Literature DB >> 27491215

Types A and B Niemann-Pick Disease.

Edward H Schuchman, Melissa P Wasserstein.   

Abstract

Two distinct metabolic abnormalities are included under the eponym Niemann-Pick disease (NPD). The first is due to the deficient activity of the enzyme acid sphingomyelinase (ASM). Patients with ASM deficiency are classified as having types A and B Niemann-Pick disease (NPD). Type A NPD patients exhibit hepatosplenomegaly, frequent pulmonary infections, and profound central nervous system involvement in infancy. They rarely survive beyond two years of age. Type B patients also have hepatosplenomegaly and progressive alterations of their lungs, but there are usually no central nervous system signs. The age of onset and rate of disease progression varies greatly among type B patients, and they frequently live into adulthood. Recently, patients with phenotypes intermediate between types A and B NPD also have been identified. These individuals represent the expected continuum caused by inheriting different mutations in the ASM gene (SMPD1). Patients in the second category are designated as having type C NPD. Impaired intracellular trafficking of cholesterol causes type C NPD, and two distinct gene defects have been found. In this chapter only types A and B NPD will be discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27491215

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  10 in total

1.  Mitochondrial biogenesis is transcriptionally repressed in lysosomal lipid storage diseases.

Authors:  King Faisal Yambire; Lorena Fernandez-Mosquera; Robert Steinfeld; Christiane Mühle; Elina Ikonen; Ira Milosevic; Nuno Raimundo
Journal:  Elife       Date:  2019-02-18       Impact factor: 8.140

2.  Increased liver tumor formation in neutral sphingomyelinase-2-deficient mice.

Authors:  Liansheng Zhong; Ji Na Kong; Michael B Dinkins; Silvia Leanhart; Zhihui Zhu; Stefka D Spassieva; Haiyan Qin; Hsuan-Pei Lin; Ahmed Elsherbini; Rebecca Wang; Xue Jiang; Mariana Nikolova-Karakashian; Guanghu Wang; Erhard Bieberich
Journal:  J Lipid Res       Date:  2018-03-22       Impact factor: 5.922

3.  Acid sphingomyelinase deficiency exacerbates LPS-induced experimental periodontitis.

Authors:  Yanchun Li; Zhongyang Lu; Lixia Zhang; Keith L Kirkwood; Maria F Lopes-Virella; Yan Huang
Journal:  Oral Dis       Date:  2020-01-30       Impact factor: 3.511

4.  A signature of enhanced lipid metabolism, lipid peroxidation and aldehyde stress in therapy-induced senescence.

Authors:  Amy C Flor; Don Wolfgeher; Ding Wu; Stephen J Kron
Journal:  Cell Death Discov       Date:  2017-10-30

Review 5.  Keep Your Friends Close, but Your Enemies Closer: Role of Acid Sphingomyelinase During Infection and Host Response.

Authors:  Ha-Yeun Chung; Ralf A Claus
Journal:  Front Med (Lausanne)       Date:  2021-01-21

6.  Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa.

Authors:  Bethanie Garside; Jan Hoong Ho; See Kwok; Yifen Liu; Shaishav Dhage; Rachelle Donn; Zohaib Iqbal; Simon A Jones; Handrean Soran
Journal:  Orphanet J Rare Dis       Date:  2021-02-27       Impact factor: 4.123

Review 7.  Bone health in patients with inborn errors of metabolism.

Authors:  M Langeveld; C E M Hollak
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

8.  Deep sequencing of SMPD1 gene revealed a heterozygous frameshift mutation (p.Ser192Alafs) in a Palestinian infant with Niemann-Pick disease type A: a case report.

Authors:  Abedelmajeed Nasereddin; Suheir Ereqat
Journal:  J Med Case Rep       Date:  2018-09-18

9.  Mutational spectrum of SMPD1 gene in Pakistani Niemann-Pick disease patients.

Authors:  Huma Arshad Cheema; Iqra Ghulam Rasool; Muhammad Nadeem Anjum; Muhammad Yasir Zahoor
Journal:  Pak J Med Sci       Date:  2020 Mar-Apr       Impact factor: 1.088

Review 10.  Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson's Disease.

Authors:  Shani Blumenreich; Or B Barav; Bethan J Jenkins; Anthony H Futerman
Journal:  Int J Mol Sci       Date:  2020-07-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.